On November 1, Aimei Vaccine announced that it has submitted a drug market registration application for its self-developed 13-valent conjugate pneumococcal vaccine to the National Medical Products Administration. The results from a completed Phase III clinical study show that Aimei's 13-valent conjugate pneumococcal vaccine has demonstrated good immunogenicity and safety, meeting the clinical preset objectives. Aimei's wholly-owned subsidiary, Aimei Biotechnology Co., Ltd., has obtained the corresponding drug production license for this product.

The 13-valent conjugate pneumococcal vaccine has been referred to as the "king of global vaccines" and has been the world's top-selling vaccine for ten consecutive years. Pfizer's 13-valent conjugate pneumococcal vaccine (Prevnar 13®) is the best-selling vaccine globally and has frequently ranked among the top ten best-selling drugs worldwide. According to Pfizer's 2023 annual report, global sales of Pfizer's pneumococcal conjugate vaccine were approximately $6.44 billion in 2023.

Over the years, the global sales of the 13-valent conjugate pneumococcal vaccine have remained high. Furthermore, the estimated penetration rate of the 13-valent conjugate pneumococcal vaccine in the approved age group in China is 25.9%, while in the corresponding age group in the United States, the penetration rate exceeds 80%, highlighting the significant growth potential in the Chinese market. In 2022, the domestic sales of this product were approximately 9.5 billion yuan, and according to ZhiShi Consulting, the market size is expected to reach 35 billion yuan by 2030. According to Aimei Vaccine's announcement, there is a global shortfall of 180 million doses of the 13-valent conjugate pneumococcal vaccine; however, only three companies globally have been approved to supply it. Aimei is expected to become an important supplier of the 13-valent conjugate pneumococcal vaccine, significantly enhancing the company's performance.

According to a report by Southwest Securities, major vaccines like the 13-valent pneumococcal vaccine have characteristics of high incidence rates, low penetration, upgrade demand, and high vaccination willingness. Companies can generate cash flow through the sales of such major products, allowing them to increase investment in their research and development pipeline, forming a positive cycle. Therefore, the launch of the 13-valent conjugate pneumococcal vaccine is expected to further drive the steady growth of Aimei Vaccine's performance.

The progress related to the 13-valent conjugate pneumococcal vaccine has consistently attracted attention from capital markets. Previously, similar companies like Watson Bio experienced positive impacts on their performance following the approval of their 13-valent conjugate pneumococcal vaccine in 2019, garnering widespread investor attention.

Data shows that since the Hong Kong stock market began to recover in September, pharmaceutical stocks have generally seen a restoration of valuations, and trading in Aimei Vaccine has also been quite active.

https://finance.eastmoney.com/a/202411013225626757.html